A Phase 3 interventional study of Salanersen in Muscular Atrophy, Spinal, sponsored by Biogen. Recruiting at 14 sites in 7 countries. Open to participants aged 0 Days to 42 Days. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Biogen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Muscular Atrophy, Spinal by Biogen — 5 open to participants now, 10 under way, 4 of them phase 3. Muscular Atrophy, Spinal · Biogen.
Among the 27 studies in Muscular Atrophy, Spinal by Biogen, this one is the 16th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2026, is one of 9 in phase 3, and was the 25th registered.
282 studies on the registry are indexed under Muscular Atrophy, Spinal; 72 are open to participants now.
Browse Muscular Atrophy, Spinal studies →5 of the 27 studies in Muscular Atrophy, Spinal by Biogen are open now, in 12 countries. Recruiting first, the newest first:
Biogen · Sites in United States
Ages 0 days–7 mo
Biogen · Sites in United States, China, Japan and 1 more country
Ages 15–60
Biogen · Sites in United States, France, Germany and 4 more countries
Ages 3+
Biogen · Sites in United States, United Kingdom
Ages 18–54 · Women only
By country, each count listing its studies:
Of the 57 Muscular Atrophy, Spinal studies recruiting now, 28 (49%) set no upper age limit and 26 (46%) stop at 75 or younger; 45 take children under 18; 11 take healthy volunteers.
This study: 0 Days to 42 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 4 · Phase 3 9 · Phase 4 1
First in 2011; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 30 is close to the median of 29 across 156 interventional studies indexed under Muscular Atrophy, Spinal.
Median enrollment 47 across the 21 interventional studies, 74 across the 5 observational. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
4 of the studies in Muscular Atrophy, Spinal by Biogen that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05067790Phase 3BiogenA Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND) | 2027-09-24 |
| NCT04317794BiogenA Study of the Safety of Nusinersen (Spinraza®) and Its Effects on Motor Function in Koreans Living With SMA Treated During Their Usual Medical Care | 2027-02-05 |
| NCT05042921BiogenPediatric Spinal Muscular Atrophy (SMA) China Registry | 2027-09-02 |
| NCT06555419BiogenA Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK) | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 27 studies in Muscular Atrophy, Spinal by Biogen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, researchers will learn more about the effects and safety of BIIB115, also known as salanersen.
Specifically, researchers will learn more about how salanersen works in babies who have been diagnosed with SMA through genetic testing but have not yet started showing signs or symptoms. Most people with SMA have changes in a gene called survival motor neuron 1, also known as SMN1. These changes lower the amount of SMN protein in their bodies. Without enough of this protein, motor neurons and muscles cannot work properly. A similar gene called SMN2 can help replace some of the lost SMN protein in the body. Salanersen works by helping the SMN2 gene to make more SMN protein.
In this study, participants will have either 2 SMN2 copies or 3 SMN2 copies. The higher the copy number, the less severe the participant's SMA is.
The main goal of this study is to see if starting salanersen before signs or symptoms appear can prevent signs or symptoms of SMA or make them less severe. Researchers will use different tests to learn if motor symptoms are changing, including the World Health Organization (WHO) motor milestones.
The main questions researchers want to answer in this study are:
Researchers will also learn more about:
This study will be done as follows:
For Part 1 of the study, the primary objective is to evaluate the clinical efficacy of salanersen in participants with genetically diagnosed SMA, and the secondary objective is to evaluate safety and tolerability, pharmacokinetics (PK), and effect on biomarkers after treatment with salanersen in participants with genetically diagnosed SMA.
For Part 2 of the study, the primary objective is to evaluate the long-term clinical efficacy of salanersen in participants with genetically diagnosed SMA, and the secondary objective is to evaluate the long-term safety and tolerability, PK, and effect on biomarkers after treatment with salanersen in participants with genetically diagnosed SMA.
Key Inclusion Criteria:
-≤42 days of age at first dose of salanersen.
Key Exclusion Criteria:
Note: Other protocol-defined inclusion/exclusion criteria will apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Part 1 of the study, participants will receive two doses of salanersen, 80 milligrams (mg) by intrathecal (IT) lumbar puncture (LP), approximately 12 months apart. Participants who complete Part 1 of the study will receive three doses of salanersen, 80 mg by IT LP, approximately 12 months apart, in Part 2 of the study.
Drug: Salanersen
Administered intrathecally
Also known as: BIIB115
Part 1: Percentage of Participants with 2 Survival Motor Neuron 2 (SMN2) Copies Sitting Without Support (for at Least 10 Seconds)
Time frame: At Month 12
Part 1: Percentage of Participants with 3 SMN2 Copies Walking Alone (for at Least 5 Steps)
Time frame: At Month 18
Part 2: Percentage of Participants Attaining and Maintaining World Health Organization (WHO) Motor Milestones
The WHO motor milestones will include six key developmental milestones: sitting without support, standing with assistance, hands-and-knees crawling, walking with assistance, standing alone, and walking alone.
Time frame: Up to Day 1825
Part 1: Percentage of Participants Attaining World Health Organization (WHO) Motor Milestones
The WHO motor milestones will include six key developmental milestones: sitting without support, standing with assistance, hands-and-knees crawling, walking with assistance, standing alone, and walking alone.
Time frame: Up to Day 730
Parts 1 and 2: Percentage of Participants Attaining Hammersmith Infant Neurological Examination Section 2 (HINE-2) Motor Milestones
Section 2 of the HINE is used to assess motor milestones and includes 8 motor milestone categories: voluntary grasp (0 to 3), ability to kick in supine position (0 to 4), head control (0 to 2), rolling (0 to 3), sitting (0 to 4), crawling (0 to 4), standing (0 to 3), and walking (0 to 3). Total HINE-2 score is the sum of points from each item and can range from 0 to 26, with higher scores depicting a better level of ability.
Time frame: Up to Day 1825
Parts 1 and 2: Change From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Motor Function Scale
The CHOP INTEND test is designed to evaluate the motor skills of participants with significant motor weakness. It includes 16 items (capturing neck, trunk, and proximal and distal limb strength) structured to move from easiest to hardest with the grading including gravity eliminated (lower scores) to antigravity movements (higher scores). All item scores range from 0-4. The total score ranges from 0-64, with higher scores depicting better motor function.
Time frame: Up to Day 1825
Parts 1 and 2: Change From Baseline in Compound Muscle Action Potential (CMAP) Amplitudes
CMAP is a well validated method for tracking disease progression in neuromuscular disorders such as SMA and amyotrophic lateral sclerosis and has been proposed as a potential biomarker of a therapeutic effect in SMA. CMAPs will be performed for the following nerve-muscle pairs: ulnar-abductor digiti minimi and peroneal-tibialis anterior.
Time frame: Up to Day 1825
Part 1: Percentage of Participants who Remain Free of Clinically Manifested Spinal Muscular Atrophy (SMA)
Time frame: Up to Day 730
Part 2: Hammersmith Functional Motor Scale Expanded (HFMSE) Total Score
The HFMSE is a tool used to assess motor function in individuals with SMA. Participants will be asked to complete a specific movement and are then graded on the quality and execution of that movement. Higher scores indicate higher levels of motor ability. The overall score is the sum of the scores for all 33 items, with a maximum score of 66 with higher scores depicting better ability to perform activities.
Time frame: Up to Day 1825
Part 2: Change From Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE)
The HFMSE is a tool used to assess motor function in individuals with SMA. Participants will be asked to complete a specific movement and are then graded on the quality and execution of that movement. Higher scores indicate higher levels of motor ability. The overall score is the sum of the scores for all 33 items, with a maximum score of 66 with higher scores depicting better ability to perform activities.
Time frame: Up to Day 1825
Part 2: Revised Upper Limb Module (RULM) Total Score
The RULM is developed to assess upper limb functional abilities of participants with SMA. This test consists of a total of 20 upper limb performance items that are reflective of activities of daily living. The RULM is scored from 0 to 37 points, with higher scores indicating better function.
Time frame: Up to Day 1825
Part 2: Change From Baseline in Revised Upper Limb Module (RULM)
The RULM is developed to assess upper limb functional abilities of participants with SMA. This test consists of a total of 20 upper limb performance items that are reflective of activities of daily living. The RULM is scored from 0 to 37 points, with higher scores indicating better function.
Time frame: Up to Day 1825
Part 2: Percentage of Participants who Develop Spinal Muscular Atrophy (SMA) Subtypes (Type 1, 2,3a and 3b) As Assessed by the Investigator
Time frame: Up to Day 1825
Parts 1 and 2: Time to Death (Overall Survival)
Time frame: Up to Day 1825
Parts 1 and 2: Time to Death or Permanent Ventilation
Permanent ventilation is defined as tracheostomy or ≥16 hours ventilation/day continuously for \>21 days in the absence of an acute reversible event.
Time frame: Up to Day 1825
Parts 1 and 2: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Up to Day 1825
Parts 1 and 2: Concentration of Salanersen in Cerebrospinal Fluid (CSF)
Time frame: Up to Day 1460
Parts 1 and 2: Concentration of Salanersen in Serum
Time frame: Up to Day 1825
Parts 1 and 2: Change From Baseline in Plasma Levels of Neurofilament Light Chain (NfL)
Time frame: Up to Day 1825
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
Started Apr 2026 (actual). Primary completion is estimated for Nov 2028, 31 months after the start.
Of 18 phase 3 interventional studies under Muscular Atrophy, Spinal, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 31 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Salanersen